SPYRE THERAPEUTICS, INC. Available-for-sale Securities, Amortized Cost Basis
SPYRE THERAPEUTICS, INC. (SYRE) had Available-for-sale Securities, Amortized Cost Basis of $32.81 million as of 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-05-08
- 2018-03-31: Available-for-sale Securities, Amortized Cost Basis $32.81M.
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $37.58M.
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $42.62M.
- 2017-06-30: Available-for-sale Securities, Amortized Cost Basis $36.49M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2018-03-31 | $32.81M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $37.58M 10-Q · filed 2018-05-08 |
| 2017-09-30 | $42.62M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $36.49M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $41.10M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $15.76M 10-K · filed 2018-03-13 |
| 2016-09-30 | $18.49M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $2.95M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $4.97M 10-Q · filed 2016-05-19 |
| 2015-12-31 | $3.77M 10-K · filed 2017-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |